AVEO Pharmaceuticals Inc. (AVEO) and Cyanotech Corporation (NASDAQ:CYAN) Comparison side by side

Both AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) and Cyanotech Corporation (NASDAQ:CYAN) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AVEO Pharmaceuticals Inc. 5.41M 13.67 5.33M -0.20 0.00
Cyanotech Corporation 32.24M 0.68 3.18M -0.21 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of AVEO Pharmaceuticals Inc. and Cyanotech Corporation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of AVEO Pharmaceuticals Inc. and Cyanotech Corporation.

Net Margins Return on Equity Return on Assets
AVEO Pharmaceuticals Inc. -98.52% 48.1% -69.9%
Cyanotech Corporation -9.86% -4.3% -2.5%

Risk & Volatility

A 1.13 beta indicates that AVEO Pharmaceuticals Inc. is 13.00% more volatile compared to Standard & Poor’s 500. In other hand, Cyanotech Corporation has beta of 0.86 which is 14.00% less volatile than Standard & Poor’s 500.

Liquidity

AVEO Pharmaceuticals Inc.’s Current Ratio is 1.1 while its Quick Ratio is 1.1. On the competitive side is, Cyanotech Corporation which has a 1.8 Current Ratio and a 0.4 Quick Ratio. Cyanotech Corporation is better positioned to pay off short and long-term obligations compared to AVEO Pharmaceuticals Inc.

Analyst Ratings

AVEO Pharmaceuticals Inc. and Cyanotech Corporation Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AVEO Pharmaceuticals Inc. 0 2 1 2.33
Cyanotech Corporation 0 0 0 0.00

The consensus target price of AVEO Pharmaceuticals Inc. is $2, with potential upside of 238.93%.

Institutional & Insider Ownership

The shares of both AVEO Pharmaceuticals Inc. and Cyanotech Corporation are owned by institutional investors at 41.9% and 28.1% respectively. Insiders owned 0.3% of AVEO Pharmaceuticals Inc. shares. On the other hand, insiders owned about 15% of Cyanotech Corporation’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AVEO Pharmaceuticals Inc. -15.19% -19.85% -72.92% -80.67% -80.4% -64.96%
Cyanotech Corporation 6.67% 24.22% 20.36% 8.75% -23.65% 32.45%

For the past year AVEO Pharmaceuticals Inc. had bearish trend while Cyanotech Corporation had bullish trend.

Summary

Cyanotech Corporation beats AVEO Pharmaceuticals Inc. on 7 of the 11 factors.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition market worldwide. The companyÂ’s products include Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the bodyÂ’s natural inflammatory response, enhance skin, and support eye and joint health. Cyanotech Corporation sells its products in bulk quantities to manufacturers, formulators, and distributors in the health foods and nutritional supplements markets; and as packaged consumer products to distributors, retailers, and direct consumers. The company also sells its products online at nutrex-hawaii.com. Cyanotech Corporation was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.